

Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of the Claims:

Claim 1 (currently amended): An immediate release pharmaceutical composition suitable for oral administration comprising:

- (i) 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline or a pharmaceutically-acceptable salt thereof (the Agent);
- (ii) a water-soluble acid present as the free acid; and
- (iii) a water-soluble cellulose ether or an ester of a water-soluble cellulose ether.

Claim 2 (previously presented): The pharmaceutical composition according to claim 1 wherein (iii) is a water-soluble cellulose ether.

Claim 3 (withdrawn and previously presented): The pharmaceutical composition according to claim 1 wherein (iii) is an ester of a water-soluble cellulose ether.

Claim 4 (previously presented): The pharmaceutical composition according to claim 1 or claim 2 wherein the water-soluble cellulose ether is selected from methyl cellulose, hydroxyethylcellulose, hydroxypropylcellulose and hydroxypropyl methylcellulose.

Claim 5 (withdrawn and previously presented): The pharmaceutical composition according to claim 1 or claim 2 wherein the water-soluble cellulose ether is methyl cellulose.

Claim 6 (previously presented): The pharmaceutical composition according to claim 1 or claim 2 wherein the water-soluble cellulose ether is hydroxypropyl methylcellulose.

Claim 7 (withdrawn and previously presented): The pharmaceutical composition according to

claim 1 or claim 3 wherein the ester of a water-soluble cellulose ether is the ester of hydroxypropyl methylcellulose or the ester of hydroxypropylcellulose wherein the ester is selected from one or more of acetate, succinate, phthalate, isophthalate, terephthalate and trimellitate.

Claim 8 (previously presented): The pharmaceutical composition according to claim 1 wherein the water-soluble cellulose ether or the ester of a water-soluble cellulose ether is selected from hydroxypropyl methylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose and hydroxypropyl methylcellulose acetate succinate.

Claim 9 (previously presented): The pharmaceutical composition according to claim 1 wherein the water-soluble acid is solid at ambient temperature.

Claim 10 (currently amended): The pharmaceutical composition according to claim 1 wherein the water-soluble acid is a water-soluble aliphatic ~~mono-~~mono- or poly-carboxylic acid which may be saturated or unsaturated.

Claim 11 (previously presented): The pharmaceutical composition according to claim 10 wherein the water-soluble acid is selected from fumaric acid and malic acid.

Claim 12 (previously presented): The pharmaceutical composition according to claim 1 wherein the molar ratio of Agent to acid is from 1:1 to 1:10.

Claim 13 (previously presented): The pharmaceutical composition according to claim 1 wherein the weight ratio of Agent to water-soluble cellulose ether, or ester of water-soluble cellulose ether is from 30:1 to 3:1.

Claim 14 (previously presented): The pharmaceutical composition according to claim 1 comprising:

(i) from 10 to 60 parts of the Agent;
(ii) from 2 to 70 parts of a water-soluble cellulose ether selected from methyl cellulose and hydroxypropyl methylcellulose; and
(iii) from 10 to 70 parts of a water-soluble organic acid selected from fumaric acid and malic acid;
wherein all parts are by weight and the sum of the parts (i)+(ii)+(iii)=100; and wherein the molar ratio of Agent to organic acid is from 1:3 to 1:6.

Claim 15 (previously presented): The pharmaceutical composition according to claim 1 wherein the Agent, the water-soluble acid, and the water-soluble cellulose ether and/or ester of a water-soluble cellulose ether are a physical mixture.

Claim 16 (currently amended): The pharmaceutical composition according to claim 1 or claim 15 which is in the form of an oral immediate release tablet, pellet, granule or capsule formulation.

Claim 17 (withdrawn and previously presented): A method for reducing inter-patient and/or intra-patient variability in bioavailability and/or plasma concentrations of the Agent in a patient in need of the Agent comprising orally administering to said patient a pharmaceutical composition according to claim 1.

Claim 18 (withdrawn and previously presented): A method for increasing the solubilisation of the Agent in an aqueous medium with a pH value similar to those found in the upper GI tract of a human comprising adding to said aqueous medium a pharmaceutical composition according to claim 1 wherein the solubilisation of the Agent from the composition is increased compared to the solubilisation of the Agent alone in the same aqueous medium.

Claim 19 (withdrawn and previously presented): A method for inhibiting the rate of precipitation of the Agent from an aqueous solution comprising adding to an aqueous medium

with a pH similar to the gastric pH in a human, a pharmaceutical composition according to claim 1.

Claim 20 (new): The pharmaceutical composition according to claim 1 wherein the water-soluble acid is present in a molar excess relative to the Agent.

Claim 21 (new): The pharmaceutical composition according to claim 1 wherein the Agent is present in a molar ratio of from 1:2 to 1:7 relative to the water-soluble acid.

Claim 22 (new): The pharmaceutical composition according to claim 21 wherein the molar ratio is from 1:3 to 1:6.

Claim 23 (new): The pharmaceutical composition according to claim 1 wherein the Agent is in the form of a pharmaceutically acceptable salt.

Claim 24 (new): The pharmaceutical composition according to claim 1 wherein the Agent is in the form of a free base.

Claim 25 (new): The pharmaceutical composition according to claim 1 wherein the composition is a solid at ambient temperature.